Buserelin as primary therapy in advanced prostatic carcinoma.

Abstract

The effectiveness of buserelin, a luteinizing hormone-releasing hormone agonist, was tested in 28 patients with Stages C or D adenocarcinoma of the prostate. Of 24 evaluable patients, there were 13 partial responses (54%) by National Prostatic Cancer Project criteria, median duration greater than 6 months. Nine patients had stable disease (38%), median duration greater than 5 months, and only two patients progressed. Performance status improved in 38%, patient-scored pain improved in 46%, and quality of life improved in 57%. Symptoms occurring during treatment consisted of hot flashes, loss of libido, and impotence. A flare of symptoms was observed in only one patient, despite a transient 25% increase in testosterone in 36% of patients. Buserelin is an effective treatment for inducing frequent and meaningful remissions in advanced prostatic cancer.

• Authors: C A Presant, M S Soloway, S S Klioze, J W Kosola, A L Yakabow, R G Mendez, P S Kennedy, M R Wyres, V L Naessig, K S Ford
• Journal: Cancer (Cancer) Vol. 56 Issue 10 Pg. 2416-9 (Nov 15 1985) ISSN: 0008-543X [Print] United States
• PMID: 3930064 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Testosterone
• Diethylstilbestrol
• Buserelin

Topics

• Adult
• Aged
• Buserelin (metabolism, therapeutic use)
• Castration
• Diethylstilbestrol (therapeutic use)
• Humans
• Male
• Middle Aged
• Pain (pathology)
• Prostatic Neoplasms (drug therapy, pathology)
• Quality of Life
• Testosterone (blood)